The patient is a 22-year-old male who presented with chief complaints of rapidly enlarging left cervical mass over 2-month period. A CT scan revealed extensive left cervical lymphadenopathy throughout, right supraclavicular lymphadenopathy, and superior mediastinal lymphadenopathy most concerning for lymphoma (Figure 1).
An excisional biopsy was performed on a left cervical lymph node (Figure 2-4) and a sample was sent for flow cytometric analysis (Figure 5). The lymph node showed effaced architecture by a diffuse sheet of monomorphic highly proliferative mature small lymphoid cells. A diagnosis T-lymphoblastic leukemia was made. The positivity for CD33 and CD13 called into question the possibility of early precursor T-LBL.
1. Early T-cell precursor lymphoblastic leukemia (ETP-ALL) is a neoplasm of T-cell lineage with a unique immunophenotype indicating early T-cell differentiation.
2. Uncommon neoplasm accounting for 10-13% of T-ALL in childhood and 5-10% of T-ALL in adults.
3. Immunophenotyping reveals a neoplastic T cell population expressing CD7, cytoplasmic or rarely surface CD3, and one or more myeloid markers such as CD34, C-KIT (CD117), HLA-DR, CD13, CD33, CD11b, and/or CD65.
4. Immunomarkers CD4, CD5 and/or CD2 may be expressed though CD5 should be expressed on <75% of the population. MPO, CD8, and CD1a are negative in ETP-ALL.
5. Myeloid associated genes and profiles may be overexpressed such as CEBPA, GATA2, CD34, CD44, and KIT. Additionally, LYL1 overexpression may be seen. Mutation profile is similar to those associated with myeloid leukemias: FLT3, RAS family, DNMT3A, NPM1, IDH1 and IDH2. NOTCH1 and CDKN1/2 are reported less.
6. ETP-ALL/LBL and T-cell ALL are treated similarly with intensive chemotherapy though optimal management remains unclear. Some regimens include: hyperCVAD therapy, nelarabine, cytarabine, fludarabine, idarubicine, and others. ETP-ALL/LBL has a poorer prognosis and lower overall survival though a consensus has not been reached and recent studies have conflicting outlooks.